Infliximab-induced psoriasis during therapy for Crohn's disease

dc.creatorSteinwurz, Flavio
dc.creatorDenadai, Rafael
dc.creatorSaad-Hossne, Rogerio
dc.creatorQueiroz, Maria Luiza
dc.creatorTeixeira, Fabio Vieira
dc.creatorRomiti, Ricardo
dc.date.accessioned2013-11-06T18:52:58Z
dc.date.accessioned2018-07-04T16:20:10Z
dc.date.available2013-11-06T18:52:58Z
dc.date.available2018-07-04T16:20:10Z
dc.date.created2013-11-06T18:52:58Z
dc.date.issued2012
dc.identifierJOURNAL OF CROHNS & COLITIS, AMSTERDAM, v. 6, n. 5, supl. 4, Part 1-2, pp. 610-616, JUN, 2012
dc.identifier1873-9946
dc.identifierhttp://www.producao.usp.br/handle/BDPI/42577
dc.identifier10.1016/j.crohns.2011.12.007
dc.identifierhttp://dx.doi.org/10.1016/j.crohns.2011.12.007
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1634534
dc.description.abstractAlthough therapy with tumor necrosis factor-alpha inhibitors (anti-TNF) provides beneficial effects in different immune inflammatory disorders, paradoxical cases of anti-THE-induced psoriasis have increasingly been reported, mostly in the setting of rheumatologic diseases. To date, less than 50 cases of infliximab-induced psoriasis in inflammatory bowel disease patients have been described. The present report was aimed at describing two new cases of infliximab-induced psoriasis during therapy for Crohn's disease and at carrying out a review on this intriguing phenomenon. (C) 2011 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.
dc.languageeng
dc.publisherELSEVIER SCIENCE BV
dc.publisherAMSTERDAM
dc.relationJOURNAL OF CROHNS & COLITIS
dc.rightsCopyright ELSEVIER SCIENCE BV
dc.rightsclosedAccess
dc.subjectBIOLOGICAL THERAPY
dc.subjectCROHN'S DISEASE
dc.subjectINFLIXIMAB
dc.subjectPSORIASIS
dc.subjectTUMOR NECROSIS FACTOR-ALPHA INHIBITORS
dc.titleInfliximab-induced psoriasis during therapy for Crohn's disease
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución